TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Lateral Postural Inclination in Parkinson's Disease : Involvement of the Basal Ganglia ?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 30 to 75 years old patient~* Parkinson disease's diagnosed since 5 years~* Treated by deep brain stimulation~* Patient with at least 6 degree lateral deviation~* Without vestibular troubles nor peripheral sensorial trouble.~Exclusion Criteria:~* Dementia (Mattis \< 130 ou MMS \<24), or severe depressive episode according to DSM IV-R criteria~* Camptocormia or incompatible anteflexion with the dispositive of measure device~* Pregnant woman, nursing mother

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Voluntary subject (Type: PLACEBO_COMPARATOR): Patient without parkinson disease, without deep brain stimulation
- Patients (Type: ACTIVE_COMPARATOR): Subthalamic stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with anterior epistaxis~Exclusion Criteria:~* Unable to consent, do not have a valid telephone number, pregnant women, prisoners, cognitively impaired individuals, diagnosis of posterior epistaxis, major trauma, bleeding disorder (such as thrombocytopenia or hemophilia), hemodynamically unstable, or had a known hypersensitivity to study medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tranexamic Acid (100 mg/mL) (Type: EXPERIMENTAL): TXA (100 mg/1mL) sprayed in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
- 0.9% Sodium Chloride (Type: PLACEBO_COMPARATOR): 0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index of 18 - 36 kg/m\^2 and body weight ≥45 kg~* HBeAg ≥500 IU/mL at Screening~* In good general health except for chronic HBV infection for ≥6 months documented, for example, by at least two measurements of HBsAg positivity and/or detectable HBV DNA ≥6 months apart~* Lack of cirrhosis or advanced liver disease~Exclusion Criteria:~* Prior treatment for chronic HBV infection with lamivudine, telbivudine, adefovir, standard of care nucleoside or nucleotide analogue (NrtI), HBV core inhibitors, or an investigational agent for HBV infection~* History or evidence of advanced liver disease or hepatic decompensation (including jaundice, ascites, portal hypertension, gastrointestinal bleeding, esophageal varices, hepatic encephalopathy)~* History or presence of clinically significant medical conditions requiring frequent medical management or pharmacologic or surgical treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ABI-H2158 plus ETV (Type: EXPERIMENTAL): ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks
- Placebo plus ETV (Type: PLACEBO_COMPARATOR): Placebo matching ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Prehospital Laryngeal Tube vs. Bag-Valve Mask Ventilation Used by Paramedics During CPR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cardiac arrest~Exclusion Criteria:~* Paramedic does not want to use laryngeal tube~* Physician on site before paramedic~* Foreign body airway obstruction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bag-valve mask ventilation (Type: ACTIVE_COMPARATOR): Bag-valve mask ventilation during CPR, i.e. traditional ventilation during CPR. Airway management with bag-valve mask ventilation and efficient ventilation: yes or no?~Intervention is Bag-valve mask ventilation during CPR
- Laryngeal Tube (Type: ACTIVE_COMPARATOR): Laryngeal Tube Ventilation during CPR, i.e. the alternative ventilation technique to be compared to the traditional technique. Airway management with laryngeal tube and efficient ventilation: yes or no?~Intervention is Ventilation through laryngeal tube during CPR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Preparation and Azithromycin to Reduce Post Cesarean Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* full term pregnancy~* undergoing labored, non-emergent cesarean section~* patient in labor~Exclusion Criteria:~Azithromycin contraindicated:~* Known hypersensitivity to azithromycin, erythromycin, macrolides or ketolide medications.~* liver dysfunction~* Prescription medications which may interact with azithromycin, such as nelfinavir or warfarin~* A history of a cardiac dysrhythmia (irregular heartbeats)~* Known hypersensitivity to iodine~* Patients carrying fetuses with known congenital anomalies~* Immunodeficiency~* Patients who are not in labor at the time of delivery~* Non-english speaking subjects or subjects with language barriers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Vaginal Preparation (Type: EXPERIMENTAL): In addition to standard care, subjects will undergo vaginal preparation (VP). A VP kit includes sponge sticks and sponges soaked in a povidone-iodine 10% solution.
- Standard Infection Procedures (Type: SHAM_COMPARATOR): The very staff will follow hospital protocols for the cesarean delivery. The subject and the infant will be provided care in accordance with current medical standards and be discharged at the discretion of the attending physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Nosocomial COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay, in any specimen prior to randomization.~* Admitted to a participating centre~* Is nosocomially acquired infection, as defined by ALL of:~* COVID19 diagnosis being made on admission day three or later;~* Admitted for a reason other than COVID19;~* Within 5 days of COVID19 diagnosis based on test collection date or initial development of symptoms, which ever was earliest.~Exclusion Criteria:~* Plan for palliation within 24 hours~* Known allergy to study medication or its components (non-medicinal ingredients)~* Ordinal scale 6 or above~* Admitted to facility for non-medical reasons including primary psychiatric diagnosis or labour and delivery.~* Pregnancy or breast feeding~* Weight less than 40kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care (Type: NO_INTERVENTION): None
- Anti SARS-CoV-2 monoclonal antibody (Type: EXPERIMENTAL): Single IV administration of an anti-SARS-CoV-2 Monoclonal antibody

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subjects with ES (including those with Down Syndrome) having completed the double-blind AC-055-305 / MAESTRO study as scheduled, i.e., who remained in the double-blind study up to Week 16 (whether or not they were still taking study drug at the end of this period).~Exclusion Criteria:~Subjects who prematurely discontinue double-blind study drug during the AC-055-305 / MAESTRO study due to:~* an AE assessed as related to the use of study drug,~* or elevated liver tests (related or unrelated to study drug).

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Macitentan (Type: EXPERIMENTAL): Macitentan 10 mg tablet, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Diabetes Mellitus Type II and Tissue Oxygenation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~We will include 30 patients who have more than a five-year history of insulin-dependent type-2 diabetes mellitus and 30 non-diabetic patients meeting the following criteria:~* 35 - 65 yrs old~* BMI \< 30~* ASA class I - III~* Abdominal surgery scheduled to last between 2- 4 hours~For Non-diabetic group:~previous BMP within the last year demonstrating glucose \< 126mg/dL~For Diabetic group:~* DMII defined as fasting plasma glucose of \> 126 mg/dL at time of diagnosis, now requiring insulin~* At least one diabetes associated vasculopathy: coronary artery disease, diabetic nephropathy, hypertension, diabetic retinopathy, diffuse neuropathy, peripheral vascular disease, or a history of stroke~Exclusion Criteria:~* Pregnant~* Immunocompromised: HIV/AIDS, on immunosuppressant therapy for any reason, or post-organ transplantation.~* Infection or fever, or on glucocorticoids~* Malignancy currently requiring radiation or chemotherapy~* Liver or renal failure~* Pancreatic insufficiency, dysautonomia, thyroid disease, Raynaud's syndrome, pathologic Allen-test, or any coagulopathies~* Respiratory disease affecting ability to reach PaO2 of 300mmHg: COPD, emphysema, cystic fibrosis, asthma, pneumonia, PE~* Smoker within the past 6 months or current alcohol abuse~* Allergy to local anesthetic~* For diabetics: DMI, other specific subtype, and gestational diabetics~* We will also exclude patients with epidural catheter, to avoid the influence of regional anesthesia on tissue oxygenation \[37, 38\].

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): None
- 2 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ChonDux for Filling Full Thickness Cartilage Defects in the Femoral Condyle of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A standing radiograph of the knee showing a Kellgren score of 0-2~* Body mass index ≤33~* An Outerbridge score of III or IV without need for bone graft~* A meniscus with no more than partial resection in the affected knee~Exclusion Criteria:~* Passive motion deficit of the knee (\>5º of extension, \>15º of flexion)~* Moderate or severe osteoarthritis~* Diabetes mellitus (IDDM Type 1)~* Patellofemoral instability~* Malalignment with \> 5° valgus or varus compared to contralateral knee~* Active osteomyelitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ChonDux plus microfracture (Type: EXPERIMENTAL): None
- Microfracture (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of clear cell renal cell carcinoma~  * Metastatic disease~ * Primary tumor is considered amenable to surgery~* Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as \> 20 mm by conventional techniques or as \> 10 mm by spiral CT scan~* No untreated brain metastases~  * Treated brain metastases allowed provided lesion has been stable on two consecutive CT or MRI scans separated by ≥ 2 months~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Leukocytes ≥ 3,000/μL~* ANC ≥ 1,500/μL~* Platelet count ≥ 75,000/μL~* Hemoglobin ≥ 8.5 g/dL~* Total Bilirubin ≤ 2 times upper limits of normal (ULN)~* AST and ALT ≤ 2.5 times ULN~* Creatinine ≤ 2.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to undergo nephrectomy and treatment with sunitinib malate~* No history of allergic reactions attributed to compounds of similar chemical or biological composition to sunitinib malate~* No uncontrolled intercurrent illness including, but not limited to, any of the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness/social situations that would limit compliance with study requirements~PRIOR CONCURRENT THERAPY:~* No prior systemic treatment with sunitinib malate~* No other concurrent investigational agents~* No concurrent combination antiretroviral therapy for HIV-positive patients~* Concurrent medications or substances known to affect, or with the potential to affect, the activity or pharmacokinetics of sunitinib malate allowed at the discretion of the principal investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Sunitinib (Type: EXPERIMENTAL): Sunitinib will be administered for 8 weeks prior to sugery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Management of Hyponatremia in Preterm Infants on Diuretics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Very low birth weight infants, 400-1500 grams~2. Bronchopulmonary dysplasia defined by an oxygen requirement greater than 30% at 4 weeks of age and chest x-ray findings consistent with developing chronic lung disease.~3. Receiving 120kcal/kg/d enterally with fortified human milk or 24 kcal/oz formula~4. Hyponatremic (defined as serum Na \<130).~Exclusion Criteria:~1. Known congenital anomalies involving the heart, lungs, kidneys, or chromosomal abnormalities.~2. Creatinine ≥ 1.3.~3. Enteral ostomy.

- Gender: ALL
- Minimum Age: 4 Weeks
- Maximum Age: 6 Months
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Randomized Optical Coherence Tomography Oslo tRial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Clinical indication for coronary angiography and intervention due to stentfailure, both stentrestenosis and stentthrombosis in stable patients or unstable patients with acute coronary syndrome.~Exclusion Criteria:~* Patient not able to give informed consent.~* Unwillingness.~* Life expectancy \< 5 years.~* Reduced kidney function with GRF\<45.~* Coronary artery diameter \< 2.5mm.~* Pregnancy.~* Patients without 11-digit Norwegian personal number.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OCT guided coronary intervention (Type: EXPERIMENTAL): Coronary angiography and optical coherence tomography imaging
- Conventional coronary intervention (Type: ACTIVE_COMPARATOR): Coronary angiography

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants born at 1,250-2g000 grams birth weight~* \<12 hours of age~* Clinical and radiographic diagnosis of respiratory distress syndrome (RDS)~* Receiving supplemental oxygen with head-hood Fi02 of 0.35 to 0.50 or CPAP Fi02 of 0.25 to 0.50 to maintain oxygen saturation less than 90 percent and more than 96 percent~Exclusion Criteria:~* Receiving mechanical ventilation~* Air leak~* Pulmonary hemorrhage~* Major congenital anomaly~* Congenital non-bacterial infection~* Parental refusal of consent~* Refusal of attending neonatologist

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Hours
- Healthy Volunteers: f

Study Arms:
- Early surfactant group (Type: EXPERIMENTAL): None
- Standard Practice group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. ECOG performance status≤2；~2. Cytologically or pathologically confirmed stage IV NSCLC ( controlled pleural effusion will be eligible) with active EGFR mutation;~3. Estimated survival time more than 3 months;~4. Age older than 18 years and under 75 years;~5. Adequate bone marrow, hepatic, and renal function;AST and ALT≤2.5 times the highest reference value when not associated with hepatic metastases, or ≤5 times when hepatic metastases occur;~6. Without history of therapy for primary and metastatic disease;~7. With pleural effusion but can be controlled;~8. Asymptomatic bone metastases without treatment;~9. Based on fusion images of 4DCT MIP sketch tumors and lymph nodes, and limit the mean lung dose: V20≤25%，V30≤18%，MLD≤14Gy，V5≤60%;~10. M1a or M1b for metastases, and the number of the distant lesions ≤10；~11. Voluntary to participate in this clinical trial and sign the consent form.~Exclusion Criteria:~1. Patients with serious functional damage of important organs;~2. Patients diagnosed adequately with other malignant tumors;~3. Pregnant or lactating women;~4. Patients in an active period of acute or chronic infectious diseases;~5. Patients who are allergic to any drugs or people with allergies;~6. With brain metastases;~7. With bone metastases needing radiotherapy;~8. Patients who participate in other clinical trials concurrently;~9. Uncontrolled pleural effusion which may intervene the radiotherapy to primary tumor in lung;~10. The number of the distant lesions\>10；~11. Patients who are considered not eligible for the trial after evaluation by investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EGFR-TKIs combined with radiotherapy (Type: EXPERIMENTAL): EGFR-TKIs combined with concurrent thoracic radiotherapy. Receive oral erlotinib 150mg per day with concurrent thoracic radiotherapy, within 2 weeks, pGTV54～60Gy/27～30f/5.5～6w.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues